Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dr. Reddy’s Warns US Market ‘Unpredictable’ As Q4 Profit Below Expectations

Executive Summary

Dr. Reddy’s Laboratories, India’s second-largest drug firm by sales, has warned that its key US export market remains “unpredictable” after reporting a lower than expected fourth-quarter net profit that capped a tough year.

You may also be interested in...



Dr Reddy’s Charts Sharp Cost Overhaul Amid Weak Q1

Dr Reddy’s plans a significant review of its “cost structure”, including potential portfolio rationalization and R&D site optimization, as part of broader efforts to emerge “leaner and agile” as it grapples with multiple business challenges that saw it post disappointing first quarter earnings.

Dr Reddy’s Charts Sharp Cost Overhaul Amid Weak Q1

Dr Reddy’s plans a significant review of its “cost structure”, including potential portfolio rationalization and R&D site optimization, as part of broader efforts to emerge “leaner and agile” as it grapples with multiple business challenges that saw it post disappointing first quarter earnings.

Dr Reddy’s Gears Biologics Expansion With GE Platform

Dr Reddy’s Laboratories hopes GE Healthcare’s FlexFactory biomanufacturing platform can deliver multiple operational gains, including a potentially more fail-safe compliance system at its site. The Indian company expects to roll out its first biosimilar MAb from the new set-up next year.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1122620

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel